Drugs / PEG-MetHuG-CSF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06698861 | Aug 2024 → Feb 2025 | — | PharmaEssentia | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-05-24 | PharmaEssentia | Results Material Information - Announcement of the Topline Results from the Phase I Clinical Trial of PharmaEssentia's Long-acting GCSF, P2203 pharmaessentia.com ↗
Material Information - Announcement of the Topline Results from the Phase I Clinical Trial of PharmaEssentia's Long-acting GCSF, P2203 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-05-24 | PharmaEssentia | Material Information - Announcement of the Topline Results from the Phase I Clinical Trial of PharmaEssentia's Long-acting GCSF, P2203 pharmaessentia.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEG-MetHuG-CSF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06698861 ↗ |
| Known as | P2203 | “A Phase I PK/PD Study of PEG-MetHuG-CSF (P2203) in Healthy Volunteers” NCT06698861 ↗ |
| Route | Subcutaneous | “Single dose of PEG-MetHuG-CSF will be given SC injection at 2 mg in Cohort 1 and 6 mg in Cohort 2” NCT06698861 ↗ |